Patent · US Active

V. cholerae hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity

US8287855B2 · kind B2 · utility

0Cited by

2References

2Claims

0Family size

Assignee

Celldex Therapeutics, Inc. · US

Inventors

Kevin Killeen · Palo Alto, US
Kenneth Roland · Mesa, US
Lawrence J. Thomas · Easton, US

Key dates

Filing date	Apr 24, 2008
Grant date	Oct 16, 2012
Priority date	—
Expiry date	Nov 8, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing Escherichia coli (ETEC) and Vibrio cholerae based on the delivery of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived from Vibrio cholerae are disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.